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Introduction
Vascular smooth muscle cells (SMCs [VSMCs]) can switch   
between differentiated (contractile) and dedifferentiated (syn­
thetic migratory) phenotypes (Gimona et al., 1990; Sobue et al., 
1999). Migration of SMCs plays a critical role in many physio­
logical and pathological processes, including atherosclerosis, 
angiogenesis, smooth muscle hypertrophy, and hyperplasia. 
PDGF is one of the most potent stimuli for migration of mesen­
chymal cell types, including VSMCs. Furthermore, excessive 
PDGF production has been implicated in several pathological 
vascular disorders (Alvarez et al., 2006; Andrae et al., 2008).
An important morphological feature of VSMCs migrating 
in vitro is a membrane structure called a podosome (Gimona   
et al., 2003; Linder and Aepfelbacher, 2003). Podosomes are 
dynamic, short­lived, actin­rich protrusions of the plasma mem­
brane, which are thought to mediate adhesion to and, in some 
cases, degradation of the surrounding extracellular matrix.   
Podosomes are also found in other migratory cells such as 
monocytes and endothelial cells (Gimona et al., 2008). Many 
types of human cancer cells as well as Rous sarcoma virus–
transformed fibroblasts form highly related structures, termed 
invadopodia, whose presence is correlated with invasive and 
metastatic behavior (Gimona et al., 2008).
MicroRNAs (miRs) are 20–25­nt­long noncoding RNAs 
that negatively regulate gene expression by binding to sites   
in the 3 untranslated region (UTR) of target mRNAs (Bartel, 
2004). These small RNA molecules are involved in processes 
such as cell differentiation and proliferation (Chen et al., 2004). 
Recently, we and others (Boettger et al., 2009; Cheng et al., 
2009;  Cordes  et  al.,  2009;  Elia  et  al.,  2009b;  Xin  et  al.,   
2009) have shown that miR­143 and ­145 regulate the VSMC 
phenotypic switch from a contractile/nonproliferative to a 
migrating/proliferative state (Owens, 1995). miR­143 and ­145 are 
organized in a cluster transcribed from the same primary miR 
S
mooth muscle cell (SMC) plasticity plays an impor-
tant  role  during  development  and  in  vascular 
  pathologies such as atherosclerosis and restenosis. 
It was recently shown that down-regulation of microRNA 
(miR)-143 and -145, which are coexpressed from a single 
promoter, regulates the switch from contractile to synthetic 
phenotype,  allowing  SMCs  to  migrate  and  proliferate. 
We show in this study that loss of miR-143/145 in vitro 
and in vivo results in the formation of podosomes, which 
are  actin-rich  membrane  protrusions  involved  in  the   
migration of several cell types, including SMCs. We further 
show that platelet-derived growth factor (PDGF) mediates 
podosome formation in SMCs through the regulation of 
miR-143/145 expression via a pathway involving Src 
and p53. Moreover, we identify key podosome regulators 
as targets of miR-143 (PDGF receptor  and protein   
kinase C ) and miR-145 (fascin). Thus, dysregulation 
of the miR-143 and -145 genes is causally involved in the 
aberrant SMC plasticity encountered during vascular dis-
ease, in part through the up-regulation of an autoregula-
tory loop that promotes podosome formation.
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whereas overexpression of Ad–miR­208 had no effect (Fig. S2 A). 
Thus, Src­mediated down­regulation of the miR-143/145 gene 
is required for the formation of podosomes. Together, these   
observations strongly suggest a key role for these miRs in regu­
lating podosome formation in VSMCs.
Previously, we demonstrated the role of the miR­143/145 
cluster in maintaining the differentiation status of VSMCs 
and proposed that their dysregulation underlies the histological 
changes observed in vessels in pathologies such as atherosclero­
sis and restenosis (Elia et al., 2009b). In this study, we show the 
ability of these cells to form podosomes, which are structures 
involved in cell migration and invasiveness, in vitro and in vivo. 
This is the first direct correlation between podosome formation 
and vascular pathologies such as atherosclerosis and restenosis. 
The miR­143/145 cluster has also been documented to play an 
important role in cancer. Dysregulation of miR­143 and ­145   
as the result of chromosomal deletion at 5q32 occurs in colon   
(Michael et al., 2003) and breast (Iorio et al., 2005) adenocarci­
nomas. Most B cell malignancies (Akao et al., 2007) and cancer 
cell lines (Michael et al., 2003) have down­regulation of both 
miRs. The presence of invadopodia, which are structurally   
related to podosomes, has been correlated with invasiveness of 
cancer cells (Weaver, 2006). In the future, it will be important to 
determine whether miR­143 and ­145, or indeed other miRs, 
regulate invadopodia formation and invasiveness in human   
cancer cells.
PDGF regulates miR-143 and -145 
expression through Src and p53 activity
PDGF is a known regulator of SMC differentiation and migra­
tion (Owens et al., 2004), and Src is known to be a key media­
tor of the PDGF signal transduction pathway (Bromann et al., 
2004). Previous studies have shown that Src family kinase sig­
naling is required to elicit both mitogenicity and motogenicity 
in response to PDGF (Kypta et al., 1990; Twamley et al., 1992; 
Klinghoffer et al., 1999). It has also been shown that PDGF 
can reduce miR­145 expression (Cheng et al., 2009). In this 
study, we found that PDGF had a similar effect on miR­143 
(Fig. 2 B). Because we demonstrated that activated Src is able 
to down­regulate miR­143/145, we next tested whether Src   
activation is the mechanism by which PDGF regulates these 
genes. Treatment with the Src family kinase inhibitor SU6656 
(Blake et al., 2000) restored miR­143 and ­145 levels in PDGF­
treated cells (Fig. 2 B). In contrast, the PI3­K (phosphatidyl­
inositol 3­kinase) inhibitor LY294002 had no effect. Next, we 
asked how Src regulates these two miRs. It has been shown 
that, once activated by PDGF, Src activity overcomes a p53­
mediated inhibition of cell cycle progression (Broome and 
Courtneidge, 2000) and that inhibition of p53 expression is   
a key phenomenon for Src­mediated podosome formation   
(Mukhopadhyay et al., 2009). Moreover, p53 activity increases 
miR­143 and ­145 levels in cancer cells in a manner that does 
not involve transcription (Suzuki et al., 2009). We hypothesized 
that in response to PDGF, Src down­regulates miR expression 
through p53 inhibition. In keeping with this, doxorubicin, a 
known p53 activator, restored miR­143 and ­145 levels in PDGF­
stimulated cells (Fig. S2 B).
(Cordes et al., 2009; Xin et al., 2009). In this study, we have 
used the knockout (KO) mouse we generated, referred to as   
the miR­143(145) KO, in which the expression of both miRs 
is prevented, to investigate the molecular mechanism under­
lying the regulation of migration by miR­143/145.
Results and discussion
The miR-143/145 gene products inhibit 
podosome formation in VSMCs
VSMCs form podosomes when they migrate and invade, so 
we first tested whether expression of these miRs affects podo­
some formation. Primary mouse aorta SMCs cultured on glass 
coverslips contained prominent actin stress fibers and large 
vinculin­containing focal adhesions. However, some (7.6 ± 2.5%) 
of the primary VSMCs obtained from miR­143(145) KO mouse 
aortas also contained podosome­like structures at the cell   
periphery (Fig. 1 A). Treatment with phorbol dibutyrate (PDBu),   
a known inducer of podosomes in SMCs (Gimona et al., 2003), 
greatly increased the number of KO cells presenting with these 
structures (91.3 ± 3.2%). These podosomes were organized 
into rings (known as rosettes), clusters of rosettes, and occa­
sionally peripheral actin belts reminiscent of the structures de­
scribed in primary osteoclasts (Fig. S1 A; Destaing et al., 2003). 
This was in stark contrast to PDBu­treated wild­type (WT) 
VSMCs, in which podosomes were present in <10% of the 
cells and found in a scattered dot­like conformation. Colocal­
ization of proteins known to be expressed in podosomes such 
as  cortactin,  vinculin,  and Tks5  (Linder  and Aepfelbacher, 
2003;  Seals  et  al.,  2005)  confirmed  that  these  structures   
were in fact podosomes (Fig. 1 B). To determine whether 
miR­143/145 loss facilitated podosome formation, we restored 
miR­143 or ­145 expression in the miR­143(145) KO VSMCs 
with the recombinant adenoviruses Ad–miR­143 or –miR­145. 
Transduction  with  either  virus  completely  abrogated  podo­
some formation (Fig. S1 B), whereas a control miR­208 had 
no effect.
Next we analyzed aortas from miR­143(145) KO and WT 
mice by immunoelectron microscopy to determine whether 
  podosomes formed in vivo. KO SMCs showed the formation   
of circular structures remarkably similar to the ones observed   
in vitro. These structures costained for the podosome proteins   
cortactin and Tks5 and were not observed in the aortas of WT 
littermates (Fig. 1 C). These data suggest that podosomes form 
in vivo, that their morphological characteristics are retained in 
tissue culture, and that miR­143/145 controls podosome forma­
tion in vivo and in vitro.
Src tyrosine kinase activity promotes podosome forma­
tion (Gimona et al., 2008); the established VSMC line A7r5 
forms abundant rosettes of podosomes when transformed with 
the constitutively active Src mutant, Src­Y527F (Furmaniak­
Kazmierczak  et  al.,  2007).  We  found  that  Src­transformed 
A7r5 cells had reduced expression of miR­143 and ­145 com­
pared with the parental cell line and that miR expression was 
partially restored by treatment with the Src inhibitor PP2 
(Fig. 2 A). In addition, overexpression of either Ad–miR­143 
or  –miR­145 inhibited the formation of podosome rosettes, 15 MicroRNAs and podosome formation • Quintavalle et al.
product derived from p53­RE­2 using two different antibodies 
against p53 (Fig. 2 F). Collectively, these data suggest that p53 
can transcriptionally regulate miR­143/145 expression through 
p53­RE­2.
Excessive  activity  of  PDGF  has  been  associated  with   
several human disorders, including atherosclerosis and resteno­
sis (Alvarez et al., 2006; Andrae et al., 2008), at least in part 
through the regulation of SMC plasticity. The mechanism un­
derling this phenomenon is not completely understood, but it 
was recently shown that miR­143 and ­145 regulate the SMC 
switch from contractile to synthetic phenotype (Boettger et al., 
2009; Cheng et al., 2009; Cordes et al., 2009; Elia et al., 2009b; 
Xin et al., 2009). In this study, we show for the first time that 
PDGF is able to regulate miR­143/145 expression via a pathway 
We analyzed the promoter region of the primary miR gene 
encoding  miR­143/145  and  identified  two  potential  binding 
sites for p53 (Fig. 2 C). To define the role of these potential p53 
response  elements  (p53­REs)  in  miR­143/145  induction,  we 
cloned a fragment from rat chromosome 18 containing the two 
potential p53­binding sites into a luciferase vector and evalu­
ated promoter activity by luciferase assay. As shown in Fig. 2 D, 
p53 activation by doxorubicin treatment induced a marked ele­
vation of miR­143/145 promoter activity. Deletion of p53­RE­2 
resulted in total inhibition of promoter activity, whereas dele­
tion of p53­RE­1 had no effect (Fig. 2 E). To test whether p53 
can bind the p53­RE­2 sequence in the endogenous promoter 
sequence of miR-143/145, we performed chromatin immuno­
precipitation (ChIP) assays. We detected one specific PCR 
Figure 1.  Podosome formation in miR-143(145) KO SMCs in vitro and in vivo. (A) Cortactin and F-actin IF to visualize podosomes in VSMCs isolated 
from WT and miR-143(145) KO mice treated with PDBu or with vehicle (Veh). Arrowheads indicate the rosettes of podosomes in miR-143(145) KO cells. 
Quantification of three separate experiments revealed podosomes in 7.6% (±2.5%) of untreated KO SMCs and in 91.3% (±3.2%) of PDBu-treated cells. 
(B) Colocalization of the podosome proteins vinculin (left) and Tks5 (right) with F-actin in KO VSMCs treated with PDBu. (C) Immunoelectron microscopy 
of miR-143(145) KO and WT aortas. White arrows indicate cortactin (10-nm gold particles), and red arrows indicate Tks5 (5-nm gold particles).   
The boxed area indicates what appears to be a rosette of podosomes located in an SMC of the miR-143(145) KO mouse, confirmed by the observa-
tion of the gold-labeled podosome markers Tks5 and cortactin in the higher magnification inset. N, nuclei; IL, intima layer. Bars: (A and B) 10 µm;   
(C) 5 µm.JCB • VOLUME 189 • NUMBER 1 • 2010   16
Figure 2.  miR-143 and -145 regulation by a pathway involving PDGF, Src, and p53. (A) Representative Northern blot for miR-143 and -145 in WT   
(WT-A7r5) and Src-Y527F–transformed (Src-A7r5) A7r5 cells treated with the Src inhibitor PP2 or with vehicle (UNT). 6h, after 6 h of treatment; o/n, after 
overnight treatment. (B) WT VSMCs were treated with PDGF in the presence or absence of the Src inhibitor SU6656 (SU) and the PI3-K inhibitor LY294002 
(LY), and miR-143 and -145 expression was evaluated by qRT-PCR. U6 small nuclear RNA was used as internal control. All measurements were calculated   
as the percentage of control (NT), and error bars were calculated as propagated standard errors of the mean of triplicate measurements from each 
  experiment. *, P < 0.05. (C) A schematic description of the putative miR-143/145 promoter with two potential p53-REs, p53-RE-1 (3176) and p53-RE-2 
(118), as compared with the p53-RE consensus, where R: A G, W: A T, and Y: C T. Lowercase letters denote deviations from the consensus. The conserved   
nucleotides C and G are highlighted in red. (D) Luciferase assays with miR-143/145 promoter vector in NIH/3T3 treated or not with doxorubicin (Doxo). The 
promoter of the MDM2 gene was used as a positive control (C (+)), whereas the promoter of E2F was used as negative control (C ()). (E) Deletion analysis 
identifies the importance of miR-143/145 p53-RE-2 in doxorubicin-mediated induction of the luciferase activity. Dashed ovals represent the deleted p53-REs. 17 MicroRNAs and podosome formation • Quintavalle et al.
in mRNA levels (Fig. 4 A and Fig. S3 B). Luciferase assays 
with WT and mutated 3 UTR–binding sites confirmed that 
these mRNAs are targets for miR­143 and ­145 (Fig. 4 B).   
All three proteins were up­regulated in KO VSMCs (Fig. S3 C). 
Both PKC­ and fascin were localized to podosomes of miR­143 
(145) KO VSMCs (Fig. S3 D), and RNA interference of either 
gene reduced podosome formation and migration in miR­143 
(145) KO VSMCs and Src­3T3 cells (Fig. 4, C and D; and   
Fig. S3, E and F).
The serine/threonine kinase PKC­ is involved in cell   
migration and proliferation. It is up­regulated in skin cancer, 
where it is responsible for increased proliferation (Breitkreutz 
et al., 2007). Although PKC activity is known to be required 
for podosome formation (Hai et al., 2002), there are no prior 
studies on the involvement of this isoform. PDGF­R is a   
receptor tyrosine kinase that stimulates both migration and pro­
liferation in response to ligand binding (Heldin and Westermark, 
1999). In SMCs, the likely ligand is PDGF­AA (Barrett and 
Benditt, 1988). Fascin is an actin­bundling protein with roles   
in diverse forms of cell protrusions and in cytoplasmic actin 
bundles (Adams, 2004). It has been shown to localize to the 
leading edge of cancer cells and play a role in their migration 
(Vignjevic et al., 2007), but it has not previously been described 
to be involved in podosome formation. We show in this study 
that each of these targets is required for podosome formation in 
VSMCs, and their inhibition, at least in part, explains the role of 
the miR-143/145 gene as an inhibitor of cell migration.
We  have  demonstrated  that  Src  activity  can  inhibit   
miR-143/145 gene expression, likely through the inhibition of 
p53 (Mukhopadhyay et al., 2009), which is a direct transcrip­
tion factor for this gene cluster. Src is an activator of podosome 
formation in VSMCs (Gimona et al., 2008; Mukhopadhyay 
et al., 2009), and it has been shown that the PKC induction   
of podosomes is a result of Src activation (Gatesman et al.,   
2004) and that Src and PKC­ can associate with each other 
(Vondriska et al., 2001). Furthermore, Src family kinases are 
activated by PDGF­Rs (Kypta et al., 1990), as is PKC­ (Ha and 
Exton, 1993). We hypothesize the presence of an autoregula­
tory loop, initiated by PDGF production in response to ves­
sel injury. Stimulation of the PDGF­R activates PKC and Src, 
which in turn promotes migration and podosome formation, 
in part through Src inhibition of p53 and thus miR­143 and ­145 
expression. This  allows  the  subsequent  up­regulation  and   
Src phosphorylation of key podosome proteins as well as   
increased expression of the PDGF­R, which further boosts 
signaling (Fig. 5).
Materials and methods
Materials
The following antibodies were used: cortactin, Tks5, and fascin (Milli-
pore); vinculin, smooth muscle -actin, and CD31 (Sigma-Aldrich); PKC-, 
involving Src and p53. The mechanism by which Src regulates 
p53 level and/or function is the subject of active investigation 
in our laboratory. Nevertheless, these results open up new po­
tential avenues to use Src and/or p53 inhibitors to treat vascular 
pathologies (Elia et al., 2009b).
PDGF induces podosome formation  
in SMCs through miR-143 and -145  
down-regulation
PDGF is a known inducer of migration in SMCs, yet stimu­
lation of podosome formation by PDGF has not previously 
been described. We pretreated A7r5 cells with PDGF for 24 h 
(allowing the complete down­regulation of the two miRs) and 
then treated the cells again with PDGF for 3 h more. After 
fixation and F­actin staining, we observed punctate structures 
in the cells (57.3 ± 2.5%; Fig. 3 A). In cells that were not pre­
treated with PDGF, far fewer cells (9.0 ± 3.6%) formed the 
same structures. When plated on gelatin­coated glass cover­
slips, these punctate structures, which costained for cortac­
tin and Tks5, were able to digest the substrate (Fig. 3 B and   
Fig. S1 C). Confocal microscopy demonstrated that the actin 
puncta colocalized in the same plane with the degradation 
spots (Fig. S2 C), confirming that they were indeed podosomes. 
Overexpression of miR­143 or ­145 during the PDGF treatment 
inhibited podosomes, demonstrating that the down­regulation 
of miR­143 and ­145 is a key step in PDGF­stimulated podo­
some formation (Fig. 3 C). When the PDGF pretreatment was 
conducted in the presence of the Src inhibitor SU6656 or 
the  p53 inducer doxorubicin, podosomes were not observed 
(Fig. 3 D). Finally, in keeping with the notion that the 24 h   
of pretreatment with PDGF is required to down­regulate the 
miRs, 80% of SMCs from miR­143(145) KO mouse aortas 
formed podosomes after only 3 h of PDGF treatment (75.3 ± 5%;   
Fig. 3 E). Before this study, only nonphysiological treatments 
such as phorbol esters had been shown to elicit podosome   
formation in SMCs. We speculate that the lengthy pretreat­
ment  with  PDGF  and  subsequent  down­regulation  of  the 
miRs might represent a physiological control mechanism that 
provides a threshold to be overcome to elicit the synthetic/ 
motile response.
Identification of targets of miR-143  
and -145
Using bioinformatics to search for miR­143 and ­145 targets, 
we identified likely candidates to be PKC­ and PDGF recep­
tor  (PDGF­R) for miR­143 and fascin for miR­145. These 
genes have highly conserved seed sequences for miR­143   
or ­145 in a variety of species (Fig. S3 A). Transduction of 
miR­143(145) KO VSMCs with Ad–miR­143 decreased the 
abundance  of  PKC­  and  PDGF­R,  whereas  transduction 
with Ad–miR­145 decreased fascin without effecting a change 
(D and E) Measurements were calculated as the percentage of control (WT promoter without doxorubicin), and error bars were calculated as propagated 
standard errors of the mean of triplicate measurements from each experiment on 3T3 cells. *, P < 0.05. (F) ChIP assay confirms that p53 specifically inter-
acts with p53-RE-2. Sequences from the upstream region of the rat miR-1 gene without p53-binding sites serve as a negative control. No Ab, isotypic IgG; 
Sc-99, p53 antibody clone sc-99; Sc-100, p53 antibody clone sc-100.
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PDGF-BB, 10 µM PP2, 5 µM SU6656, 1 µM doxorubicin, 5 µM LY294002, 
and 10 µM UO126.
Cell lines
A7r5 rat SMCs and 3T3 cells were maintained in DME (Invitrogen) supple-
mented with 1.5 g/l-glucose, 4 mM l-glutamine, 10% fetal bovine serum, and 
penicillin/streptomycin at 37°C in a 5% CO2 atmosphere. Primary VSMCs 
PDGF-R, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH; 
Cell Signaling Technology); and p53 clones sc-99 and sc-100 and isotypic 
IgG clone sc-2025 (Santa Cruz Biotechnology, Inc.). Secondary antibodies 
conjugated to Alexa Fluor 488 and 568 and Alexa Fluor 594–conjugated 
phalloidin were obtained from Invitrogen. PDBu, PDGF-BB, PP2, SU6656, 
doxorubicin, LY294002, and UO126 were purchased from Sigma-Aldrich 
and used at the following concentrations: 10 µM PDBu, 10 and 20 ng/ml 
Figure 3.  Podosome formation induced by PDGF 
in WT and KO SMCs. (A) Cortactin and F-actin   
IF to visualize podosomes in A7r5 treated with   
10 ng/ml PDGF for 24 + 3 h or only for 3 h. Quanti-
fication of three independent experiments showed 
no podosome formation under normal conditions, 
whereas 57.3% (±2.5%) of cells had podosomes 
after PDGF treatment. The inset indicates an area 
of  podosome  formation  (boxed  area).  (B)  FITC-
gelatin degradation assay on A7r5 cells treated 
with PDGF. (C) Cortactin and F-actin IF to visualize 
podosomes in A7r5 cells induced by PDGF and 
treated with different adenoviruses (Ad). (D) Cor-
tactin and F-actin IF to visualize podosomes in A7r5 
cells induced by PDGF and treated with different 
compounds  (SU6656  and  doxorubicin  [Doxo]). 
(E) Cortactin and F-actin IF to visualize podosomes 
in VSMCs isolated from miR-143(145) KO mice 
treated with 10 ng/ml PDGF or not treated (NT).   
In three separate experiments, 75.3% (±5%) of KO 
VSMC formed rosettes of podosomes after PDGF 
treatment. (B, C, and E) Arrows indicate areas of 
podosome formation. Bars, 10 µm.19 MicroRNAs and podosome formation • Quintavalle et al.
dissected and fixed in 2% paraformaldehyde, 0.1% glutaraldehyde, and 
0.1 M sodium phosphate in PBS, pH 7.2, for 24 h. After fixation, aortas 
were treated with 1% osmium tetrachloride and dehydrated using graded 
ethanol. The samples were then infiltrated with and embedded in LX112 
epoxy resin (Ted Pella, Inc.). Ultrathin sections (83 nm) were made using 
an Ultracut II (Leica) and placed on 150-mesh nickel grids. Sections were 
then steamed for 20 min in a citrate-based antigen retrieval solution. When 
cool, the sections were then blocked using serum-free protein block.   
Each section was then probed for the primary antibodies for 2 h, fol-
lowed by gold secondary antibodies (5- and 10-nm gold particle from 
Ted Pella, Inc.) at 1:20 dilution in TBS, pH 7.6, for 1 h. Sections were 
viewed, and images were obtained using an electron microscope (EM10C; 
Carl Zeiss, Inc.).
were obtained from WT and KO mouse aortas, and purity was assessed by 
staining with antibodies against smooth muscle -actin and CD31 as previ-
ously described (Ray et al., 2001). 99% of the cells were positive for smooth 
muscle -actin.
Animals
Animals were housed in accordance with the guidelines of the American   
Association for Laboratory Animal Care. The miR-143(145) KO mice were 
previously described (Elia et al., 2009b).
Electron microscopy
Electronic microscopy was performed at the Veterans Medical Research 
Foundation, San Diego, CA. Adult aortas from WT and KO mice were 
Figure 4.  miR-143 and -145 targets. (A) Representative immunoblot of primary VSMCs isolated from miR-143(145) KO mice transduced with adenovirus 
(Ad-miR) with an empty expression cassette () or expressing miR-143, -145, or -208. (B) Luciferase reporter assay on 3T3 cells performed by cotransfec-
tion of 20 nM miR-143, miR-145, or scrambled oligonucleotide (+) with a renilla reporter gene linked to 10 ng WT (wt) or mutated (mt) 3 UTR of PKC-, 
PDGF-R, or fascin. All measurements were calculated as the percentage of control (WT 3 UTR), and error bars were calculated as propagated standard 
errors of the mean of triplicate measurements from each experiment. *, P < 0.03 versus control scrambled miR. (C) Morphology of KO VSMCs with a 
knockdown of PKC- and fascin by lentiviral shRNA interference. (D) Migration of KO VSMCs with a knockdown of PKC- and fascin by lentiviral shRNA 
interference. All measurements were calculated as the percentage of scrambled control, and error bars were calculated as propagated standard errors of 
the mean of triplicate measurements from each experiment. *, P < 0.05. Bar, 10 µm.JCB • VOLUME 189 • NUMBER 1 • 2010   20
Bioinformatics
Potential miR-143 and -145 targets were identified using the algorithms   
miRanda (http://www.microrna.org), TargetScan (http://www.targetscan 
.org),  and  PicTar  (http://pictar.mdc-berlin.de/)  as  previously  described 
(Carè et al., 2007; Elia et al., 2009a).
Formaldehyde cross-linking and ChIP assay
ChIP assays were performed as previously described (Fazi et al., 2005). 
In brief, cross-linking of proteins to DNA was obtained by the direct addi-
tion of formaldehyde to cultured cells (2 × 10
6) to a final concentration of 
1%. After incubation for 10 min at 37°C, the mixture was sonicated, and 
chromatin was immunoprecipitated overnight with 5 µl of p53 antibodies. 
miR-143/145  promoter  analysis  was  performed  using  MatInspector 
(http://www.genomatix.de/products/MatInspector). Binding sites were 
amplified  using  the  primers  p53-RE-2–5  (5-TAAGCCCCTCTCATCTC-
CCAACAG-3), p53-RE-2–3 (5-GGAACAATGGGATGGGGAGGTATG-3),   
foxo3a-RE–5 (5-GACTCTGTATTAATCTGCTTTAC-3), and foxo3a-RE–3 
(5-GCAGTGCTCAAATGGTACCAG-3).
Reporter assays
The miR-143/145 promoter, which contains two potential binding sites for 
p53, was amplified from rat chromosome 18 using KOD Taq polymerase 
(EMD) and the primers p53-5 (5-TAAGCCCCTCTCATCTCCCA-3) and 
p53-3 (5-GACTCCCAACTGACCAGAGA-3). The promoter was cloned 
into the reporter plasmid pGL3-basic (Promega). For the promoter experi-
ment, 3T3 cells were seeded in 24-well plates (Nunc) and transfected with 
100 ng of the miR-143/145 promoter-luciferase reporter construct and   
10 ng of the renilla plasmid using Lipofectamine 2000 (Invitrogen) and 
then treated with 1 µM doxorubicin. The deleted promoter sequences were   
obtained using the primers BS1-5 (5-CCTCCCCATCCCATTGTTCC-3), 
BS1-3 (5-GACTCCCAACTGACCAGAGA-3), BS2-5 (5-TAAGC-
CCCTCTCATCTCCCA-3), and BS2-3 (5-ACGTCCATCTTCGTGTCCT-
TTG-3). For the 3 UTR reporter assay, experiments were performed in 3T3 
cells. 3 UTR segments were subcloned by standard procedures into the 
psiCHECK-2 (Promega) immediately downstream of the stop codon of   
the renilla gene using the primers PKC-–5 (5-GAGGCTGCTTCGGATG-
GAGGGA-3), PKC-–3 (5-TAAGATTTAACATCATCATATT-3), fascin-5 
(5-GGCCACCTGCCCTCTGCAGG-3), fascin-3 (5-GGCCGCAGACT-
TGATTTTAC-3), PDGF-R–5 (5-CTGACACGCTCCGGGTATCA-3), and 
PDGF-R–3 (5-AACGTTAAGTCATATATAAT-3). Seed sequence muta-
genesis was performed as described by the manufacturer (Agilent Technolo-
gies). 3T3 cells were transfected with 10 ng of the reporter plasmid and   
20 nM of the miR mimics or scrambled sequence (Thermo Fisher Scientific)   
using Lipofectamine 2000 according to the manufacturer’s protocol (Invit-
rogen). Cells were lysed and assayed for luciferase activity at 48 h after 
transfection, and the luciferase gene coexpressed in the same plasmid was 
used as internal control. All luciferase assays were performed with Dual   
Luciferase kit (Promega) as previously described (Carè et al., 2007; Elia   
et al., 2009a).
RNA interference
Smart pool siRNAs for scrambled, PKC-, and fascin were purchased from 
Thermo Fisher Scientific and transfected into Src-3T3 using Lipofectamine 
2000. Lentiviruses with scrambled, PKC-, and fascin short hairpin RNA 
(shRNA) were purchased from Santa Cruz Biotechnology, Inc., and KO 
SMCs were infected at MOI 5 using 5 µg/ml polybrene. Cells were selected 
for puromycin resistance according to the manufacturer’s protocol. RNA 
  silencing was evaluated by qRT-PCR, and the residual levels of RNA for 
each target were as follows: PKC-, 15 ± 0.9 in Src-3T3 and 10 ± 1.3 in 
SMCs; and fascin, 34 ± 4 in Src-3T3 and 30 ± 1.4 in SMCs.
RNA quantification
For qRT-PCR analysis, total RNA was extracted using the TRIZOL reagent 
(Invitrogen) according to the manufacturer’s protocol. cDNA was prepared 
using  SuperScript  Reverse  transcription  cDNA  kit  (Invitrogen).  SYBR 
green qRT-PCR was performed using the primers PKC-–5 (5-CTGGAC-
GTGGACTCCTGATT-3), PKC-–3 (5-ACTCAGGCTCCTTCCATCA-3),   
fascin-5 (5-AACCCCTTGCCTTTCAAACT-3), fascin-3 (5-CATGGAA-
AGAAGGGGACAGA-3), PDGF-R–5 (5-AGGACTTGGGTGATGTG-
GAG-3), PDGF-R–3 (5-TGTGGCCAGTCACTCTCTTG-3), GAPDH-5 
(5-GACGGCCGCATCTTCTTGT-3), and GAPDH-3 (5-CACACCGACC-
TTCACCATTTT-3). For miR qRT-PCR, total RNA was extracted using TRIZOL. 
Primers and probes specific for mouse/rat miR-143, -145, and -199 and 
internal control, Sno202 RNA, and U6 small nuclear RNA were purchased 
from Applied Biosystems. Amplification and detection was performed 
with a sequence detection system (model 7300; ABI) using 40 cycles of 
Immunofluorescence (IF)
IF was performed on paraformaldehyde-fixed cells. Cells were permea-
bilized with 0.1% Triton X-100 in PBS and then blocked with 0.1% Triton 
X-100 and 5% BSA in PBS for 1 h, washed, and incubated overnight 
with the related antibody at 4°C. Antibodies conjugated to Alexa Fluor 
488 and 568 were used as secondary antibodies. Actin was visualized 
with Alexa Fluor 594–conjugated phalloidin, and nuclei were stained 
with DAPI. Coverslips were mounted with Mounting Medium for Fluores-
cence (Vectashield; Vector Laboratories). Fluorescence microscopy images 
were obtained with a microscope (Axioplan2; Carl Zeiss, Inc.) equipped 
with a charge-coupled device camera (Axiocam HRm; Carl Zeiss, Inc.) 
using Axiovision software (Carl Zeiss, Inc.) at room temperature. All   
images of primary cells were taken with a 40× NA 0.75 objective.   
The A7r5 cells were imaged with a 63× NA 1.40 oil immersion objective. 
Confocal images were obtained with a microscope (Radiance 2100 MP; 
Bio-Rad Laboratories) using Laser Sharp 2000 software (Bio-Rad Labora-
tories) at room temperature (60× NA 1.4, zoom 7, Pix0.027 oil immer-
sion objective). Postacquisition analyses were performed using Volocity 
software (PerkinElmer).
Podosome function and migration assays
Functional assays were performed essentially as described previously 
(Berdeaux et al., 2004). Quantification of podosomes was performed 
on merged phalloidin-cortactin–stained samples on at least 50 randomly   
chosen fields representing 100 total cells per experimental point. Primary 
WT and KO cells containing at least one complete rosette of podosomes 
were scored as positive. A7r5 cells containing at least two punctate   
F-actin–rich podosomes were scored as positive. Total cell numbers were 
calculated by scoring the number of nuclei on the same field. Motility and 
invasion assays using Transwell chambers were conducted as described 
previously (Seals et al., 2005), except that 10,000 cells were used in each 
assay and it was performed for 6 h. Adenovirus infection was performed 
24 h before the assay, whereas PDBu was added directly to the culture   
medium during the seeding of the Boyden chamber (BD). PDGF was used 
as a chemoattractant.
Generation of adenoviral vectors harboring miRs
Adenovirus vectors were prepared as previously described (Carè et al., 
2007; Elia et al., 2009a). Cells were transduced at an MOI of 50 and 
checked for adequate transduction by quantitative RT-PCR (qRT-PCR).
Figure 5.  Model for the role of miR-143 and -145 in VSMC migration and 
podosome formation. Vascular stress triggers the PDGF response, which 
activates Src, which in turn inhibits p53 and thus represses miR-143 and 
-145 expression. This relieves miR-143 repression of the expression of   
PKC- and PDGF-R and miR-145 repression of fascin, allowing the forma-
tion of podosomes and an increased migratory capacity. Thus, loss of both 
miRs increases the activity of pathways involved in cell migration.21 MicroRNAs and podosome formation • Quintavalle et al.
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